Pyxis Oncology (PYXS) Cash & Current Investments (2020 - 2026)

Pyxis Oncology (PYXS) has reported Cash & Current Investments for 6 consecutive years, with $66.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Current Investments fell 47.33% year-over-year to $66.9 million; the TTM figure through Dec 2025 stood at $66.9 million (down 47.33% YoY), while the FY2025 annual figure was $66.9 million, down 47.33% from the prior year.
• Cash & Current Investments fell to $66.9 million in Q4 2025 per PYXS's latest filing, from $76.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $276.2 million in Q4 2021 and bottomed at $12.2 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $118.9 million across 5 years, with a median of $129.9 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Current Investments soared 1086.88% — and 2023, when it sank 87.83%.
• Pyxis Oncology's Cash & Current Investments stood at $276.2 million in 2021, then tumbled by 34.55% to $180.8 million in 2022, then slumped by 34.0% to $119.3 million in 2023, then rose by 6.4% to $126.9 million in 2024, then tumbled by 47.33% to $66.9 million in 2025.
• Business Quant data shows PYXS's Cash & Current Investments at $66.9 million in Q4 2025, $76.3 million in Q3 2025, and $12.2 million in Q2 2025.